Logo image of UTMD

UTAH MEDICAL PRODUCTS INC (UTMD) Stock Fundamental Analysis

NASDAQ:UTMD - Nasdaq - US9174881089 - Common Stock - Currency: USD

57.04  -0.73 (-1.26%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to UTMD. UTMD was compared to 187 industry peers in the Health Care Equipment & Supplies industry. UTMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. UTMD has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

UTMD had positive earnings in the past year.
UTMD had a positive operating cash flow in the past year.
In the past 5 years UTMD has always been profitable.
Each year in the past 5 years UTMD had a positive operating cash flow.
UTMD Yearly Net Income VS EBIT VS OCF VS FCFUTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

1.2 Ratios

The Return On Assets of UTMD (11.32%) is better than 93.58% of its industry peers.
The Return On Equity of UTMD (11.81%) is better than 87.70% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.46%, UTMD belongs to the top of the industry, outperforming 90.37% of the companies in the same industry.
UTMD had an Average Return On Invested Capital over the past 3 years of 12.32%. This is above the industry average of 7.89%.
Industry RankSector Rank
ROA 11.32%
ROE 11.81%
ROIC 9.46%
ROA(3y)12.3%
ROA(5y)11.87%
ROE(3y)13.06%
ROE(5y)12.7%
ROIC(3y)12.32%
ROIC(5y)12.29%
UTMD Yearly ROA, ROE, ROICUTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

UTMD's Profit Margin of 33.92% is amongst the best of the industry. UTMD outperforms 97.86% of its industry peers.
In the last couple of years the Profit Margin of UTMD has grown nicely.
The Operating Margin of UTMD (33.23%) is better than 100.00% of its industry peers.
In the last couple of years the Operating Margin of UTMD has remained more or less at the same level.
UTMD has a Gross Margin (59.03%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of UTMD has remained more or less at the same level.
Industry RankSector Rank
OM 33.23%
PM (TTM) 33.92%
GM 59.03%
OM growth 3Y-0.06%
OM growth 5Y0.46%
PM growth 3Y4%
PM growth 5Y1.55%
GM growth 3Y-2.17%
GM growth 5Y-1.24%
UTMD Yearly Profit, Operating, Gross MarginsUTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

10

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTMD is still creating some value.
Compared to 1 year ago, UTMD has less shares outstanding
Compared to 5 years ago, UTMD has less shares outstanding
There is no outstanding debt for UTMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UTMD Yearly Shares OutstandingUTMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
UTMD Yearly Total Debt VS Total AssetsUTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 25.12 indicates that UTMD is not in any danger for bankruptcy at the moment.
The Altman-Z score of UTMD (25.12) is better than 95.19% of its industry peers.
There is no outstanding debt for UTMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 25.12
ROIC/WACC1.05
WACC9.04%
UTMD Yearly LT Debt VS Equity VS FCFUTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 25.64 indicates that UTMD has no problem at all paying its short term obligations.
UTMD has a better Current ratio (25.64) than 100.00% of its industry peers.
A Quick Ratio of 23.29 indicates that UTMD has no problem at all paying its short term obligations.
The Quick ratio of UTMD (23.29) is better than 99.47% of its industry peers.
Industry RankSector Rank
Current Ratio 25.64
Quick Ratio 23.29
UTMD Yearly Current Assets VS Current LiabilitesUTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

UTMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.50%.
Measured over the past 5 years, UTMD shows a small growth in Earnings Per Share. The EPS has been growing by 0.16% on average per year.
Looking at the last year, UTMD shows a very negative growth in Revenue. The Revenue has decreased by -18.57% in the last year.
Measured over the past years, UTMD shows a decrease in Revenue. The Revenue has been decreasing by -2.70% on average per year.
EPS 1Y (TTM)-13.5%
EPS 3Y-0.66%
EPS 5Y0.16%
EPS Q2Q%-27.33%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-5.87%
Revenue growth 5Y-2.7%
Sales Q2Q%-25.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UTMD Yearly Revenue VS EstimatesUTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.44 indicates a correct valuation of UTMD.
Compared to the rest of the industry, the Price/Earnings ratio of UTMD indicates a rather cheap valuation: UTMD is cheaper than 87.17% of the companies listed in the same industry.
UTMD is valuated rather cheaply when we compare the Price/Earnings ratio to 27.93, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.44
Fwd PE N/A
UTMD Price Earnings VS Forward Price EarningsUTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, UTMD is valued cheaply inside the industry as 96.79% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, UTMD is valued cheaply inside the industry as 93.58% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.7
EV/EBITDA 6.39
UTMD Per share dataUTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The excellent profitability rating of UTMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)93.02
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 2.10%, UTMD has a reasonable but not impressive dividend return.
UTMD's Dividend Yield is rather good when compared to the industry average which is at 1.78. UTMD pays more dividend than 96.26% of the companies in the same industry.
UTMD's Dividend Yield is comparable with the S&P500 average which is at 2.32.
Industry RankSector Rank
Dividend Yield 2.1%

5.2 History

The dividend of UTMD has a limited annual growth rate of 1.95%.
UTMD has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of UTMD decreased in the last 3 years.
Dividend Growth(5Y)1.95%
Div Incr Years2
Div Non Decr Years2
UTMD Yearly Dividends per shareUTMD Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

30.70% of the earnings are spent on dividend by UTMD. This is a low number and sustainable payout ratio.
The dividend of UTMD is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP30.7%
EPS Next 2YN/A
EPS Next 3YN/A
UTMD Yearly Income VS Free CF VS DividendUTMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M
UTMD Dividend Payout.UTMD Dividend Payout, showing the Payout Ratio.UTMD Dividend Payout.PayoutRetained Earnings

More info and screens

UTAH MEDICAL PRODUCTS INC

NASDAQ:UTMD (7/29/2025, 1:03:41 PM)

57.04

-0.73 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-24 2025-04-24
Earnings (Next)07-29 2025-07-29
Inst Owners70.84%
Inst Owner Change-0.64%
Ins Owners7.04%
Ins Owner Change0%
Market Cap185.38M
Analysts0
Price TargetN/A
Short Float %3.54%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield 2.1%
Yearly Dividend1.22
Dividend Growth(5Y)1.95%
DP30.7%
Div Incr Years2
Div Non Decr Years2
Ex-Date06-16 2025-06-16 (0.305)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 14.44
Fwd PE N/A
P/S 4.53
P/FCF 12.7
P/OCF 12.5
P/B 1.58
P/tB 1.84
EV/EBITDA 6.39
EPS(TTM)3.95
EY6.92%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.49
FCFY7.87%
OCF(TTM)4.56
OCFY8%
SpS12.59
BVpS36.13
TBVpS31.07
PEG (NY)N/A
PEG (5Y)93.02
Profitability
Industry RankSector Rank
ROA 11.32%
ROE 11.81%
ROCE 11.44%
ROIC 9.46%
ROICexc 31.39%
ROICexgc 58.06%
OM 33.23%
PM (TTM) 33.92%
GM 59.03%
FCFM 35.68%
ROA(3y)12.3%
ROA(5y)11.87%
ROE(3y)13.06%
ROE(5y)12.7%
ROIC(3y)12.32%
ROIC(5y)12.29%
ROICexc(3y)38.7%
ROICexc(5y)33.39%
ROICexgc(3y)78.49%
ROICexgc(5y)75.65%
ROCE(3y)14.9%
ROCE(5y)14.86%
ROICexcg growth 3Y-5.7%
ROICexcg growth 5Y-2.21%
ROICexc growth 3Y5.77%
ROICexc growth 5Y9.65%
OM growth 3Y-0.06%
OM growth 5Y0.46%
PM growth 3Y4%
PM growth 5Y1.55%
GM growth 3Y-2.17%
GM growth 5Y-1.24%
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 8.41%
Cap/Sales 0.57%
Interest Coverage 250
Cash Conversion 90.49%
Profit Quality 105.2%
Current Ratio 25.64
Quick Ratio 23.29
Altman-Z 25.12
F-Score6
WACC9.04%
ROIC/WACC1.05
Cap/Depr(3y)10.06%
Cap/Depr(5y)9.94%
Cap/Sales(3y)1.14%
Cap/Sales(5y)1.32%
Profit Quality(3y)119.58%
Profit Quality(5y)135.38%
High Growth Momentum
Growth
EPS 1Y (TTM)-13.5%
EPS 3Y-0.66%
EPS 5Y0.16%
EPS Q2Q%-27.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-5.87%
Revenue growth 5Y-2.7%
Sales Q2Q%-25.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.01%
EBIT growth 3Y-5.93%
EBIT growth 5Y-2.25%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.56%
FCF growth 3Y-10.92%
FCF growth 5YN/A
OCF growth 1Y-33.44%
OCF growth 3Y-11.23%
OCF growth 5Y-2.76%